Jan Schouten
Overview
Explore the profile of Jan Schouten including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
33
Citations
731
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Spekreijse L, Simons R, Winkens B, van den Biggelaar F, Dirksen C, Bartels M, et al.
Lancet
. 2023 May;
401(10392):1951-1962.
PMID: 37201546
Background: In an ageing population, efficiency improvements are required to assure future accessibility of cataract care. We aim to address remaining knowledge gaps by evaluating the safety, effectiveness, and cost-effectiveness...
2.
van Helden M, Zwarthoff S, Arends R, Reinieren-Beeren I, Parade M, Driessen-Engels L, et al.
J Immunother Cancer
. 2023 Apr;
11(4).
PMID: 37068796
Background: Preclinical studies have firmly established the CD47-signal-regulatory protein (SIRP)α axis as a myeloid immune checkpoint in cancer, and this is corroborated by available evidence from the first clinical studies...
3.
Groothuis P, Jacobs D, Hermens I, Damming D, Berentsen K, Mattaar-Hepp E, et al.
Mol Cancer Ther
. 2023 Apr;
22(6):765-777.
PMID: 37042205
MET, the cell-surface receptor for the hepatocyte growth factor/scatter factor, which is widely overexpressed in various solid cancer types, is an attractive target for the development of antibody-based therapeutics. BYON3521...
4.
Strunk A, Abbes A, Stuitje A, Hettinga C, Sepers E, Snetselaar R, et al.
Int J Neonatal Screen
. 2020 Oct;
5(2):21.
PMID: 33072980
Spinal muscular atrophy (SMA) is one of the leading genetic causes of infant mortality with an incidence of 1:10,000. The recently-introduced antisense oligonucleotide treatment improves the outcome of this disease,...
5.
Intragenic and structural variation in the locus and clinical variability in spinal muscular atrophy
Wadman R, Jansen M, Stam M, Wijngaarde C, Curial C, Medic J, et al.
Brain Commun
. 2020 Sep;
2(2):fcaa075.
PMID: 32954327
Clinical severity and treatment response vary significantly between patients with spinal muscular atrophy. The approval of therapies and the emergence of neonatal screening programmes urgently require a more detailed understanding...
6.
Coumans R, Ariaans G, Spijker H, Renart Verkerk P, Beusker P, Kokke B, et al.
Bioconjug Chem
. 2020 Jul;
31(9):2136-2146.
PMID: 32697078
Engineering cysteines at specific sites in antibodies to create well-defined ADCs for the treatment of cancer is a promising approach to increase the therapeutic index and helps to streamline the...
7.
Vijzelaar R, Snetselaar R, Clausen M, Mason A, Rinsma M, Zegers M, et al.
PLoS One
. 2019 Jul;
14(7):e0220211.
PMID: 31339938
Spinal Muscular Atrophy (SMA) is a disorder characterized by the degeneration of motor neurons in the spinal cord, leading to muscular atrophy. In the majority of cases, SMA is caused...
8.
Schouten J, van Vught P, Galjaard R
Methods Mol Biol
. 2018 Dec;
1885:161-170.
PMID: 30506197
Multiplex Ligation-dependent Probe Amplification (MLPA) is a method to determine the copy number of up to 60 genomic DNA sequences in a single multiplex PCR based reaction.MLPA probes consist of...
9.
Zhang J, Bekkers E, Chen D, Berendschot T, Schouten J, Pluim J, et al.
IEEE Trans Biomed Eng
. 2018 Apr;
65(5):1151-1165.
PMID: 29683430
Objective: In this paper, we propose a robust, efficient, and automatic reconnection algorithm for bridging interrupted curvilinear skeletons in ophthalmologic images. Methods: This method employs the contour completion process, i.e.,...
10.
Benard-Slagter A, Zondervan I, de Groot K, Ghazavi F, Sarhadi V, Van Vlierberghe P, et al.
J Mol Diagn
. 2017 Jul;
19(5):659-672.
PMID: 28736295
Recurrent and clonal genetic alterations are characteristic of different subtypes of T- and B-cell lymphoblastic leukemia (ALL), and several subtypes are strong independent predictors of clinical outcome. A next-generation sequencing-based...